The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer

Fan, Helen G. Mar; Park, A.; Xu, Wei; Yi, Q-L.; Braganza, S.; Chang, José; Couture, Félix; Tannock, Ian F.

doi:10.1002/pon.1372

Cited by 44 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two RCTs have been performed looking at differences in breast cancer patients randomised to receive erythropoetin or placebo during adjuvant chemotherapy. One assessed cognitive function from 12 to 30 months post chemotherapy and found no difference in cognitive function between the two groups at any time point [167]. The second study reported improved executive functioning during chemotherapy (prior to cycle 4) in the erythropoetin group, but no difference in cognitive function at 6 months follow-up in comparison to the placebo group [106].…”

Section: Potential Mechanismsmentioning

confidence: 96%

Cognitive function after chemotherapy in adults with solid tumours

Vardy

Tannock

2007

Critical Reviews in Oncology/Hematology

191

138

View full text Add to dashboard Cite

Section: Potential Mechanismsmentioning

confidence: 96%

Cognitive function after chemotherapy in adults with solid tumours

Vardy

Tannock

2007

Critical Reviews in Oncology/Hematology

191

138

View full text Add to dashboard Cite

“…Most pharmacological treatment studies of cancer patients and survivors have centered on treating side effects of chemotherapy such as fatigue 109–112 and anemia, 113,114 and have largely not focused on treating cognitive symptoms associated with chemotherapy. Studies evaluating the efficacy of stimulants, such as methylphenidate, dexmethylphenidate, and modafinil, for the treatment of CRCI have yielded mixed results with respect to cognition, therefore it remains unclear whether these medications are useful in treating CRCI.…”

Section: Interventionmentioning

confidence: 99%

Cognitive Effects of Chemotherapy and Cancer-Related Treatments in Older Adults

Vega

Dumas

Newhouse

2017

The American Journal of Geriatric Psychiatry

View full text Add to dashboard Cite

Advances in cancer treatment are producing a growing number of cancer survivors; therefore, issues surrounding quality of life during and following cancer treatment have become increasingly important. Chemotherapy-related cognitive impairment (CRCI) is a problem that is commonly reported following the administration of chemotherapy treatment in patients with cancer. Research suggests that CRCI can persist for months to years after completing treatment, which has implications for the trajectory of normal and pathologic cognitive aging for the growing number of long-term cancer survivors. These problems are particularly relevant for older individuals given that cancer is largely a disease of older age, and the number of patients with cancer who are age 65 years or older will increase dramatically over the coming decades. This review will briefly summarize empirical findings related to CRCI, discuss CRCI in older patients with cancer, potential causative hypotheses, and provide a canonical patient case to illustrate how CRCI presents clinically. Finally, potential intervention strategies for CRCI will be highlighted and issues to consider when evaluating older patients with a history of cancer will be discussed.

show abstract

“…Controversial data were obtained about the efficacy of erythropoietin on cognitive function in women following chemotherapy for breast cancer. A recent study failed to demonstrate a beneficial effect of epoetin-alfa against the delayed cognitive impairment after chemotherapy [28].…”

Section: Cognitive Impairment Treatment In Cancer Survivorsmentioning

confidence: 98%